Article
Sofosbuvir plus ribavirin and sofosbuvir plus ledipasvir in patients with genotype 1 or 3 hepatitis C virus and severe renal impairment: a multicentre, phase 2b, non-randomised, open-label study.
The lancet. Gastroenterology & hepatology - 1 Oct 2020
Lawitz Eric, Landis Charles S, Flamm Steven L, Bonacini Maurizio, Ortiz-Lasanta Grisell, Huang Jonathan, Zhang Jie, Kirby Brian J, De-Oertel Shampa, Hyland Robert H, Osinusi Anu O, Brainard Diana M, Robson Richard, Maliakkal Benedict J, Gordon Stuart C, Gane Edward J
Abstract excerpt
BACKGROUND: There is a medical need for highly effective, safe, and well tolerated treatments for patients infected with hepatitis C virus (HCV) with severe renal impairment. We investigated the safety and efficacy of sofosbuvir with ribavirin or ledipasvir combined with sofosbuvir in a prospective study of patients with genotype 1 or 3 HCV infection and stage 4-5 chronic kidney disease (creatinine clearance by...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.